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Abstract In response to bradykinin, phosphorylated MAP
kinases (ERK-1 and ERK-2) were abundantly increased in
HEK 293 cells, which overexpress the rat B2 kinin receptor. In a
similar way des-Arg9-bradykinin stimulation of B1 kinin
receptor-overexpressing HEK 293 cells caused activation of the
same species of MAP kinase. Furthermore, nuclear translocation
of transcription factor AP-1 was also found in the cells after
stimulation with either agonist. PD98059, a MAP kinase kinase
(MEK-1) inhibitor, blocked the agonist-induced AP-1 transloca-
tion as well as the phosphorylation of the MAP kinases. This
communication provides the first evidence for both B1 and B2
kinin receptors mediating the MAP kinase signaling pathway to
activate AP-1.
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1. Introduction
Kinins, which are peptides released from high-molecular-
weight precursor kininogens by limited proteolysis, are known
to exert a variety of physiological and pathological e¡ects,
including smooth muscle contraction, vasodilation, vascular
permeability increase, and pain production [1^3]. The exis-
tence of two subtypes of kinin receptors, B1 and B2, has
been proposed based on pharmacological grounds [4,5], and
this has been substantially supported by cDNA cloning and
expression [6,7]. The B2 kinin receptor is constitutively ex-
pressed in a variety of tissues and has a high binding a⁄nity
for bradykinin (BK) and for Lys-BK (kallidin), but not for
their respective carboxypeptidase degradation products, des-
Arg9-BK and des-Arg10-kallidin [8]. The B1 kinin receptor, in
contrast, is expressed de novo under certain pathological con-
ditions, and exhibits no a⁄nity for BK or kallidin but has a
high a⁄nity for des-Arg9-BK and des-Arg10-kallidin [9]. The
two receptors are known as members of the family of G-pro-
tein coupled, transmembrane seven-span proteins [10], and the
signaling leads to inositol phosphate activation to increase
intracellular Ca2 [11]. However, precise characterization of
the signaling pathways after agonist stimulation is lacking,
especially in B1 receptor-mediated signaling. There are some
papers showing activation of the mitogen-activated protein
(MAP) kinase pathway by BK through the B2 kinin receptor
to cause phosphorylation of cytosolic phospholipase A2 [12]
and transactivation of the epidermal growth factor receptor
[13] ; however, there is no information on the B1 receptor.
Transcription factor activator protein-1 (AP-1) is known to
be activated not only by c-Jun N-terminal kinase (JNK) but
also by the MAP kinase pathway [14]. Involvement of the
MAP kinase pathway in AP-1 activation has been described
in the case of angiotensin II receptors, but there is no infor-
mation on kinin receptors in this regard [15].
We recently reported that des-Arg9-BK induced hypoten-
sion via the B1 kinin receptor, which was induced by lipo-
polysaccharide treatment in rats [16]; and induction of con-
traction of isolated rat ileum by des-Arg9-BK allowed partial
characterization of the receptor [17,18]. Recently we isolated
and cloned rat cDNA of B1 and B2 receptors and over-
expressed them in HEK 293 cells. In the study communicated
here we characterized and compared B1 and B2 receptors in
these cells, especially focussing on the cellular signalling path-
way after agonist stimulation.
2. Materials and methods
2.1. Materials
Bradykinin, des-Arg9-bradykinin, D-Arg-[Hyp3,Thi5;8,D-Phe7]BK
and Hoe 140 were purchased from the Peptide Institute (Osaka).
Des-Arg10-Hoe 140 was from Research Biochemicals (Natick, MA).
PD98059 was from Biomol (Plymouth Meeting, PA). Anti-phosphory-
lated MAP kinase and JNK antibodies were purchased from Promega
(Madison, WI), rabbit polyclonal antibodies against Fos/Jun (anti-c-
Fos, anti-c-Jun, anti-JunB, anti-JunD), from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA), and [3H]des-Arg10-[Leu9]-kallidin and [3H]BK
from DuPont-New England Nuclear (Boston, MA). FR190997 [19]
was generously donated by Fujisawa Pharmaceutical Co., Tsukuba
Research Labs (Ibaraki). Des-Arg9-NPC17731 was a gift from Dr.
D.J. Kyle (Scios Nova, Sunnyvale, CA).
2.2. Stable expression of rat B1 or B2 kinin receptors in HEK 293 cells
cDNAs for rat B1 and B2 kinin receptors were obtained by means
of the polymerase chain reaction using Sprague-Dawley rat genomic
DNA as a template. Primers (B2 : sense 5P-GAAATGTTCAACAT-
CACCACGC-3P, antisense 5P-GATGGCTTGTGTTCACTGCTTGT-
T-3P, B1 : sense 5P-ATGGCGTCCGAGGTCTTGTT-3P, antisense 5P-
TTATAAAGTCCCCAGAACC-3P) were synthesized according to the
nucleotide sequence of rat B1 and B2 kinin receptors reported by
Chao et al. [20,21]. The obtained DNAs were subcloned into the
pCR 3.1 expression vector (Invitrogen, San Diego, CA) and se-
quenced by the dideoxy method. The plasmid DNA transfection of
human embryonic kidney cells (HEK 293) was performed by the use
of Cell Fectin (Life Technologies, Grand Island, NY) and the cells
showing the highest expression of B1 or B2 kinin receptor mRNAs
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were selected among G418-resistant transformants (HEK 293/B1 or
HEK 293/B2).
2.3. Agonist stimulation of B1 or B2 kinin receptor-overexpressed cells
HEK 293, HEK 293/B2 or HEK 293/B1 cells were grown in RPMI
1640 medium (Life Technologies) supplemented with 10% fetal bovine
serum (Atlanta Biologicals, Atlanta, GA). After an 18 h incubation in
4 ml of serum-free RPMI 1640 medium (1U105 cells/60 mm dish),
stimulation was started by the addition of BK or des-Arg9-BK to the
medium and terminated by removing the medium by aspiration, fol-
lowed by the addition of 1.4 ml of ice-cold phosphate-bu¡ered saline.
In the case of the experiment using a MAP kinase inhibitor, the cells
were incubated with the inhibitor, PD98059, at 37‡C for 20 min, and
then BK or des-Arg9-BK was added.
2.4. Electrophoretic mobility shift assay (EMSA)
Double-stranded oligonucleotides containing consensus sequences
were radiolabeled with [K-32P]dCTP (Amersham, Arlington Heights,
IL) at their 3P end with a Klenow fragment and then puri¢ed with a
MicroSpin column (Pharmacia, Uppsala). The sense sequences of
synthesized oligonucleotides used were as follows: AP-1, 5P-CGCTT-
GATGATGCAGC-CGGAA-3P ; mutated AP-1, 5P-CGCTTGACGC-
AATCGCCGGAA-3P ; NF-UB, 5P-TTAACAGAGGGGACTTTCC-
GAG-3P ; and CREB, 5P-AGAGATTGCCTGACGTCAGAGAGC-
TAG-3P.
Nuclear extracts of the cells were prepared as follows: the sus-
pended cells in 200 Wl of ice-cold bu¡er A (10 mM HEPES, 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT), 0.5
mM phenylmethylsulfonyl £uoride (PMSF), 2 Wg/ml leupeptin, 2 Wg/
ml pepstatin, 2 Wg/ml aprotinin; pH 7.9) were incubated for 10 min on
ice, Nonidet P-40 was added to the suspension at a ¢nal concentration
of 0.4% (v/v) and the mixtures were vortexed vigorously for 10 s; and
then the nuclei were pelleted by centrifugation at 15 000Ug for 1 min.
The pellets were suspended in 30 Wl of bu¡er C (20 mM HEPES, 0.4 M
NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM
PMSF, 2 Wg/ml leupeptin, 2 Wg/ml pepstatin, 2 Wg/ml aprotinin; pH
7.9) by vigorous mixing for 5 min at 4‡C. After centrifugation at
10 000Ug for 5 min, the supernatants were used as nuclear extract.
The nuclear extracts were incubated with 1 ng of radiolabeled AP-1 or
NF-UB oligonucleotide in binding bu¡er (10 mM HEPES, 50 mM
KCl, 5 mM MgCl2, 0.5 mM EDTA, 5 mM DTT, 0.7 mM PMSF,
2 Wg/ml leupeptin, 2 Wg/ml pepstatin, 2 Wg/ml aprotinin, 10% (v/v)
glycerol, 1 Wg/ml poly(dI-dC)Wpoly(dI-dC), pH 7.9) for 30 min at
25‡C. For competition assay, 100-fold excess of unlabeled oligonu-
cleotide was added to the binding reaction prior to the addition of the
radiolabeled probe. For supershift analysis, 1 Wg of the indicated anti-
bodies were added following the binding reaction for 1 h at 4‡C. Then
these incubation mixtures were electrophoresed in 4.5% native poly-
acrylamide gels with Tris borate-EDTA bu¡er. The gels were dried
and analyzed with a BAS2000 (Fuji Photo Film, Kanagawa).
2.5. SDS-PAGE/immunoblotting
The cells at a density of 5U106 cells/ml in PBS containing 0.1%
SDS were lysed, applied to SDS-polyacrylamide gels, and electropho-
resed as previously reported [22]. Then the proteins were electro-
blotted onto nitrocellulose membranes. The membranes were blocked
for 1 h in 10 mM TBS containing 0.1% Tween-20 (TBS-T) and 3%
skim milk. After the membranes had been washed with TBS-T, anti-
body against phosphorylated MAP kinase was added at a 1:4000
dilution in TBS-T, and incubation was carried out for 40 min. After
washing of the membranes with TBS-T, horseradish peroxidase-con-
jugated goat anti-rabbit IgG (Jackson Immunoresearch, West Grove,
PA) was added at a 1:10 000 dilution in TBS-T, and the membrane
was incubated for 40 min. After a ¢nal washing of the membranes
with TBS-T, protein bands were visualized with an ECL Western blot
analysis system (Amersham).
3. Results and discussion
3.1. Functional properties of the B1 and B2 kinin receptors
in receptor-overexpressed cells
Nucleotide sequences of the rat B2 kinin receptor gene ob-
tained here from the Sprague-Dawley rat as well as from the
Brown Norway rat were completely homologous with the
published sequence [20], whereas B1 receptor cDNAs obtained
from both strains diverged from the GenBank-registered se-
quence [21] at positions 310, 311, and 314, where bases G, C,
and A were found instead of C, A and G, respectively. This
resulted in a change in the amino acid at position 104 from Q
to A and at position 105 from C to E.
To con¢rm the functional properties of the B1 and B2 kinin
receptors thus obtained, we prepared cells overexpressing
these receptors (HEK 293/B1 and HEK 293/B2, B1 and B2
receptors, respectively) and examined them for their ligand
binding and ligand induced calcium in£ux (data not shown).
HEK 293/B1 and HEK 293/B2 cells each showed receptor-
speci¢c ligand binding ([3H]des-Arg10-[Leu9]-kallidin for B1
receptor and [3H]BK for B2 receptor) and also responded
with an increase in intracellular calcium when stimulated
with each receptor-speci¢c ligand (des-Arg9-BK for B1 recep-
tor and BK for B2 receptor). These agonist-induced increases
in intracellular calcium were inhibited by the corresponding
receptor-speci¢c antagonists, i.e. des-Arg9-NPC17731 for the
B1 receptor and D-Arg-[Hyp3,Thi5;8,D-Phe7]BK for the B2 re-
ceptor. These binding properties and intracellular calcium re-
sponse are mostly compatible with observations made on hu-
man B2 or B1 kinin receptor-overexpressed cells [23,24]. Thus
HEK 293/B1 and HEK 293/B2 cells were proved to express
the agonist-stimulated functions through each receptor type.
3.2. Agonist-induced translocation of AP-1 in the B1 or B2
receptor-overexpressed cells
Using these receptor-overexpressed cells, we examined the
signal transduction pathway after B1 and B2 receptor stimu-
lation by a speci¢c agonist. First of all we determined whether
transcription factors AP-1 and NF-UB were activated. Un-
transfected HEK 293 cells showed no increased AP-1 binding
activity, but B2 receptor stimulation with BK but not with
des-Arg9-BK induced translocation of AP-1 into the nuclear
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Fig. 1. Translocation of AP-1 in the B1 or B2 receptor-overex-
pressed HEK 293 cells by the activation with BK or des-Arg9-BK.
Untransfected HEK 293 cells (293), transfected HEK 293 cells with
B2 receptor (293/B2) or transfected HEK 293 cells with B1 receptor
(293/B1) were stimulated with BK (1 WM, BK), des-Arg9-BK (1 WM,
dABK), FR190997 (1 WM, FR) or vehicle (lane C) for 120 min. Nu-
clear extracts were prepared from the cells and subjected to EMSA
as described in Section 2. Patterns representative of those found in
three independent experiments are shown.
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fraction in HEK 293/B2 cells ; and also stimulation of HEK
293/B1 cells with des-Arg9-BK showed this translocation (Fig.
1). However, stimulation with not only des-Arg9-BK but also
BK showed increased AP-1 binding activity in HEK 293/B1
cells that expressed only B1 receptor, and this activation by
BK was inhibited by a B1 antagonist. By a preliminary experi-
ment, HEK 293/B1 cells did not express B2 agonist binding,
i.e. [3H]BK binding or displacement of [3H]des-Arg10-[Leu9]-
kallidin with BK (data not shown). Therefore, the action of
BK on the B1 receptor may be explained by the degradation
of BK to des-Arg9-BK during the 120 min incubation, with
the latter acting on the B1 receptor. That is, the increased
AP-1 binding may not be a consequence of the direct action
of BK itself. BK is well known to be labile in biological £uids,
being cleaved in a few minutes by peptidases on the cell mem-
brane [8]. Then we examined the e¡ect of the novel B2 agonist
FR190997, which was reported to be a non-peptide stable
agonist [19]. This compound induced AP-1 binding activity
only in HEK 293/B2 cells but not HEK 293/B1 cells (Fig.
1). We could not ¢nd any NF-UB activation in these cells
(data not shown).
3.3. Detection of nuclear factors bound to the AP-1 consensus
oligonucleotide by supershift analysis
Competitive and supershift analyses were performed with
nuclear extracts prepared from des-Arg9-BK-stimulated
HEK 293/B1 cells. The AP-1 complex was speci¢cally com-
peted by the 100-fold addition of unlabeled AP-1 probe, but
not by the 100-fold addition of NF-UB, CREB, or mutated
AP-1 probes (Fig. 2A). To identify nuclear proteins that in-
teracted with the AP-1 consensus oligonucleotide, supershift
analyses were performed by means of speci¢c antibodies
against Jun/Fos families. The c-Jun and c-Fos antibodies ef-
fectively supershifted the protein-DNA complex (indicated by
arrows to the right of the EMSA in Fig. 2B), although anti-
bodies to either JunB or JunD did not result in a discernible
supershift. Similar result was observed in BK-stimulated HEK
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Fig. 3. E¡ect of B1 and B2 receptor antagonists on the translocation
of AP-1 in HEK 293 cells following the activation with agonist.
HEK 293/B2 or HEK 293/B1 cells were pretreated with Hoe 140
(3 WM, HOE), a B2 antagonist, or with des-Arg10-Hoe 140 (3 WM,
dAHOE), a B1 antagonist, and then stimulated with BK (1 WM) or
des-Arg9-BK (1 WM, dABK) for 120 min. Nuclear extracts were
prepared from the cells and subjected to EMSA as described in Sec-
tion 2. Results representative of those found in three independent
experiments are shown.
Fig. 2. E¡ect of cold competitors and antibodies on the pattern of
AP-1 complex in EMSA. Nuclear extracts were prepared from HEK
293/B1 cells stimulated by des-Arg9-BK (1 WM, 120 min), incubated
for 30 min with or without 100-fold excess of unlabeled AP-1, mu-
tated AP-1 (mt AP-1), NF-UB, or CREB probes (A). Antibodies
(1 Wg) were added following the binding reaction for 1 h at 4‡C
(B), and then assayed for AP-1 binding activity as described in Sec-
tion 2. Arrows to the right indicate the speci¢c supershifted com-
plexes. Similar results were obtained in two other independent ex-
periments.
Fig. 4. E¡ect of MEK inhibitor PD98059 on the translocation of
AP-1 in HEK 293 cells following activation with agonist. HEK 293/
B2 or HEK 293/B1 cells were pretreated with PD98059 (0.3, 3,
30 WM) and then stimulated with BK (1 WM) or des-Arg9-BK
(1 WM, dABK) for 120 min. Nuclear extracts were prepared from
the cells and subjected to EMSA as described in Section 2. Similar
results were found in two other independent experiments.
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293/B2 cells (data not shown). These results demonstrate that
c-Jun/c-Fos heterodimers are major components of the AP-1
consensus oligonucleotide binding complex activated by ago-
nist-stimulation of B1 and B2 kinin receptors.
3.4. E¡ect of B1 and B2 antagonists on the agonist-induced
AP-1 activation
Pretreatment with B2 antagonist Hoe 140 but not with B1
antagonist des-Arg10-Hoe 140 inhibited BK-induced AP-1 ac-
tivation in HEK 293/B2 cells. On the other hand, des-Arg9-
BK and BK-induced AP-1 activation in HEK 293/B1 cells was
inhibited by the pretreatment with des-Arg10-Hoe 140, but not
with HOE 140 (Fig. 3). These results indicate that BK-in-
duced AP-1 activation in HEK 293/B2 cells is mediated by
the B2 receptor and that des-Arg9-BK and BK-induced
AP-1 activation in HEK 293/B1 cells occurs via the B1 recep-
tor, with BK acting as des-Arg9-BK on the B1 receptor for the
above-stated reason. Then, we studied further the signal trans-
duction of these two receptors.
3.5. Involvement of MAP kinase pathway in agonist-induced
AP-1 activation
We examined the possible involvement of MAP kinases in
the AP-1 activation by B1 and B2 receptors. As shown in Fig.
4, pretreatment with PD98059, a MAP kinase kinase MEK-1
inhibitor [25,26], dose-dependently suppressed the AP-1 acti-
vation in both HEK 293/B1 and HEK 293/B2 cells when the
cells were stimulated with des-Arg9-BK and BK, respectively.
Further, we explored factors in the MAP kinase pathways
and found activation of MAP kinases ERK-1 and ERK-2, as
shown in Fig. 5. Phosphorylated ERK-1 and ERK-2 were
detected in the HEK 293/B1 and HEK 293/B2 cells by immu-
noblotting with antibody against phosphorylated ERKs fol-
lowing a 5 min stimulation with each agonist. Pretreatment
with PD98059 also suppressed ERK activation in both types
of cells, suggesting that agonist stimulation of B1 and B2
receptors causes activation of ERK-1 and ERK-2 in the
MAP kinase pathway via MEK-1. However, phosphorylated
JNK-1 and JNK-2 were not detected, either before or after
the cells were stimulated with agonist (data not shown). These
results suggest that the MAP kinase ERK but not JNK, could
be involved in B1 and B2 receptor-mediated AP-1 activation.
Huang et al. reported that microinjection of an ERK-speci¢c
substrate peptide into mouse epidermal cells inhibited the in-
duction of AP-1 activity and that the overexpression of ERK-
1 augmented AP-1 activation in their evaluation of the role of
ERKs in tumor promotion [27]. Therefore, based on current
information a possible pathway could be the following: phos-
phorylated ERKs may activate AP-1 through phosphoryla-
tion of TCF/EIK-1 and thereby induce c-Fos synthesis or
act indirectly through unknown downstream mediators ; but
further precise study is necessary to clarify the mechanism of
the activation of AP-1.
In this study we demonstrated that both B1 and B2 receptor
activation by agonists caused AP-1 activation in cells over-
expressing either receptor, but could not ¢nd any trace of NF-
UB activation during the time period examined. However,
there is a report showing bradykinin-induced NF-UB activa-
tion in human ¢broblasts that led to IL-1 gene expression [28].
This discrepancy may be attributable to di¡erent cell types or
animal species of receptors. With respect to AP-1 activation,
stimulation of various autacoid receptors, such as those for
endothelin and angiotensin II, has been reported to induce
AP-1 activation through the MEK/ERK signaling pathway.
Although BK was already known to activate MAP kinase
pathway through the B2 kinin receptor [12,13], there had
been no information on the B1 receptor in this regard until
now. We have demonstrated herein that both B1 and B2 re-
ceptors activate AP-1 through the MAP kinase pathway, sug-
gesting that agonist stimulation of these receptors could con-
tribute to the expression of AP-1-dependent genes and
thus play a crucial role in physiological and pathological
e¡ects. The fact that this pathway was activated similarly
through both B1 and B2 receptors may suggest a similar
functional activity of these two receptors, although these
receptors are expressed under biologically di¡erent circum-
stances [4,29].
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